YANKCOM Partnership’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.67M Buy
10,217
+54
+0.5% +$13.8K 0.93% 23
2026
Q2
$2.56M Buy
10,163
+302
+3% +$65K 0.92% 22
2026
Q1
$2.14M Buy
9,861
+222
+2% +$49.2K 0.88% 22
2025
Q4
$2.2M Sell
9,639
-236
-2% -$53.8K 0.94% 20
2025
Q3
$2.29M Buy
9,875
+109
+1% +$22.2K 1.03% 19
2025
Q2
$1.81M Buy
9,766
+227
+2% +$42.2K 0.89% 22
2025
Q1
$2M Sell
9,539
-169
-2% -$32.9K 1.1% 17
2024
Q4
$1.73M Buy
+9,708
New +$1.78M 0.92% 21

Other funds holding ABBV

YANKCOM Partnership's ABBV Position: Q3 2026 in Review

YANKCOM Partnership increased its AbbVie (ABBV) stake by 0.53% in Q3 2026, buying an estimated $13.8K and bringing the position to 10,217 shares worth $2.67M. The position accounts for 0.93% of the portfolio, ranked #23.

YANKCOM Partnership first reported a position in ABBV in Q4 2024 and has held it in 8 quarters since. 3,064 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • YANKCOM Partnership held 10,217 shares of AbbVie worth $2.67M as of Q3 2026.
  • YANKCOM Partnership bought 54 AbbVie shares in Q3 2026, an estimated $13.8K.
  • AbbVie made up 0.93% of YANKCOM Partnership's portfolio in Q3 2026, its #23 holding.
  • YANKCOM Partnership first reported a position in AbbVie in Q4 2024 and has held it in 8 quarters since.
  • 3,064 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on YANKCOM Partnership's 13F filing for Q3 2026, filed 15 Oct 2026.